Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Global microRNA profiling of metastatic conjunctival melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Increased incidence of melanoma in situ in Denmark from 1997 to 2011: results from a nationwide population-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Persistent postoperative pain and sensory changes following lymph node excision in melanoma patients: a topical review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P
OriginalsprogEngelsk
TidsskriftMelanoma Research
Vol/bind22
Udgave nummer4
Sider (fra-til)287-93
Antal sider7
ISSN0960-8931
DOI
StatusUdgivet - 2012

ID: 36809418